However, in pathological conditions such as tissue injury or cancer, this FST and myofibroblast barrier might be disrupted, allowing activin A to cross the FST barrier and activate the ACVR2B/ACVR1B receptor complex in urothelial cells as a paracrine signal (Figure 10B). Here, ACVR2B is linked to cancer.